产品商业化和监管审批 - 公司专注于心血管健康和降低心血管风险的治疗品的商业化和开发[96] - VASCEPA在美国和欧洲获得批准上市[96,105,106] - 公司正在推进VASCEPA在中国的监管审批和商业化[110] - 公司正在最后一年的三年计划内,在全球50个主要心血管代谢市场提交并获得VASCEPA的监管批准[113] 产品销售和商业化 - 公司的商业化产品VASCEPA获得美国FDA批准用于降低三酰甘油水平和降低心血管风险[96] - 美国市场上VASCEPA面临多家仿制药竞争[100,101,102] - 欧洲市场VASCEPA的商业化进度取决于各国的价格和报销谈判[106,108] - 公司正在采取措施提高VASCEPA在欧洲的可及性和商业化效率[108] - 公司在美国以外地区的VASCEPA销售毛利率较高,因为直接销售给客户而非通过合作伙伴[117] - 公司在美国市场的VASCEPA产品收入净额同比下降27%，主要由于美国销售下降32%[131] - 公司在欧洲市场的VASCEPA产品收入净额同比增加483%[131] - 公司从合作伙伴获得的VASCEPA产品收入净额为0.2百万美元[131] - 产品收入净额同比下降31%,主要由于美国VASCEPA销售下降37%[145] - 欧洲产品收入净额增加到540万美元[145] - 来自合作伙伴的产品收入净额增加到540万美元[145] 国际合作与拓展 - 公司正在拓展国际合作伙伴关系以拓展海外市场[99,109] - 公司在2016年3月与Biologix FZCo签订协议,在中东和北非几个国家注册和商业化VASCEPA[111] - 公司在2017年9月与HLS Therapeutics Inc.签订协议,在加拿大注册、商业化和分销VASCEPA[112] - 公司与多家公司签订协议,在澳大利亚、新西兰、韩国、东南亚、以色列和希腊等地商业化和分销VAZKEPA[113,114] 研发和临床试验 - 公司自2011年开始,REDUCE-IT心血管结局研究一直是研发的核心,并已有超过40个临床指南和共识声明更新推荐使用VASCEPA[115] - 公司2024年第二季度支持了多项关于VASCEPA机理和安全性的数据发表[115] 组织重组和成本管控 - 公司实施了组织重组计划以精简业务模式并降低成本[98,99] - 公司任命新的总裁兼首席执行官接替前任[97] - 公司的整体毛利率从64%下降至48%,主要由于产品售价下降[133] - 公司的销售、一般及管理费用同比下降24%,主要由于销售费用和员工成本的减少[134][135][136] - 公司的研发费用同比下降16%,主要由于REDUCE-IT研究和固定剂量组合项目的费用减少[138][139] - 公司在上一年度实施了组织重组计划,导致重组费用1000万美元[140] - 销售、一般及管理费用同比下降29%,主要由于销售费用和一般管理费用的减少[149][150] - 研发费用同比下降9%,主要由于REDUCE-IT研究和固定剂量组合项目的费用减少[153][154] - 无需计提重组费用[155] - 2023年7月,公司实施了ORP计划,在美国和海外裁减了约30%的员工,每年减少了5000万美元的运营成本[161] 财务状况 - 现金及现金等价物和受限现金为2.164亿美元,短期投资为9070万美元[160] - 经营活动现金流出1540万美元[160] - 截至2024年6月30日止六个月期间,经营活动所用现金净额增加,主要是由于2024年进行了存货采购和重组付款,而2023年同期未发生这些[161] - 截至2024年6月30日止六个月期间,投资活动提供的现金净额增加,主要是由于1.33亿美元的投资级计息工具到期收回,部分被990万美元的投资级计息工具购买所抵消[161] - 截至2024年6月30日止六个月期间,筹资活动所用现金净额增加,主要是由于股票期权行权收入减少[161] - 截至2024年6月30日,公司应收账款净额为1.237亿美元,流动存货为2.394亿美元,长期存货为7130万美元,累计亏损为16亿美元[161] - 公司预计未来期间的季度净现金流出将继续波动,这是由于原料药采购时间、美国的仿制药竞争以及VAZKEPA在欧洲的定价和报销情况[161] - 截至2024年6月30日,公司现金及现金等价物为2.159亿美元,短期投资为9070万美元,预计现金及投资足以支持至少一年的预计运营[162] - 公司的合同义务主要包括与供应链合作方的采购义务和房地产租赁,没有特殊目的实体或其他资产负债表外安排[163] 其他 - 公司的许可和专利收入同比增加33%,主要由于在中国获得REDUCE-IT适应症的里程碑付款[132] - 公司的其他收益净额同比下降95%,主要由于上一年度获得了CARES法案下的纳税抵免[142] - 2024年1月,公司宣布启动最高50亿美元的股票回购计划,已获得股东和英国高等法院的批准,但尚未开始实施[161] - 市场风险方面,与年度报告中的披露相比没有重大变化[164]

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a b ...

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a b ...

Uncovering affordable breakthrough stocks under $10 in the portfolio can lead to high-price return opportunities. Here, the focus is on three such stocks, each demonstrating strong fundamentals that signal high upside potential.The first company’s top prospects include continued revenue growth, significant improvements in gross margins and successful strategic expansions. These position the company for robust future performance in the environmentally sustainable carbon products sector.On the other hand, the ...

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD)1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement ...

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.   To enhance engag ...

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Amari ...

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Amari ...

Bangkok, Thailand, June 07, 2024 (GLOBE NEWSWIRE) -- LA BOUTIQUE This new location promises to be a premier destination for high-end fashion enthusiasts and tourists visiting Bangkok, Thailand. Celebrating 12 years in the fashion industry, LA BOUTIQUE has consistently pushed the boundaries of design and innovation, creating timeless pieces that captivate audiences worldwide. The brand’s exquisite collections have been worn by international celebrities such as Eva Longoria, Olivia Palermo, and Kristina Baza ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...